Indonesia Ophthalmic Drugs Market Size & Outlook
Indonesia ophthalmic drugs market, 2018-2030 (US$M)
Related Markets
Indonesia ophthalmic drugs market highlights
- The Indonesia ophthalmic drugs market generated a revenue of USD 551.2 million in 2023 and is expected to reach USD 1,204.9 million by 2030.
- The Indonesia market is expected to grow at a CAGR of 11.8% from 2024 to 2030.
- In terms of segment, anti-vegf agents was the largest revenue generating drug class in 2023.
- Anti-VEGF agents is the most lucrative drug class segment registering the fastest growth during the forecast period.
Ophthalmic drugs market data book summary
| Market revenue in 2023 | USD 551.2 million |
| Market revenue in 2030 | USD 1,204.9 million |
| Growth rate | 11.8% (CAGR from 2023 to 2030) |
| Largest segment | Anti-vegf agents |
| Fastest growing segment | Anti-VEGF agents |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Anti-Allergy, Anti-VEGF agents, Anti-inflammatory, Anti-glaucoma |
| Key market players worldwide | Pfizer Inc, Alcon Inc, Novartis AG ADR, Bausch Health Companies Inc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, AbbVie Inc, Bayer AG, Genentech, Nicox SA Share from reverse split, Coherus BioSciences Inc |
Other key industry trends
- In terms of revenue, Indonesia accounted for 1.5% of the global ophthalmic drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan ophthalmic drugs market is projected to lead the regional market in terms of revenue in 2030.
- Indonesia is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,204.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Ophthalmic Drugs Market Scope
Ophthalmic Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Indonesia ophthalmic drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to ophthalmic drugs market will help companies and investors design strategic landscapes.
Anti-vegf agents was the largest segment with a revenue share of 32.8% in 2023. Horizon Databook has segmented the Indonesia ophthalmic drugs market based on anti-allergy, anti-vegf agents, anti-inflammatory, anti-glaucoma covering the revenue growth of each sub-segment from 2018 to 2030.
The rising prevalence of retinal disorders and lack of knowledge associated with the diagnosis and treatment of retinal disorders are fueling the need for the development of novel therapeutics in the country. The pharmaceutical market in Indonesia is the largest in Southeast Asia.
However, 90% of raw materials used to manufacture medicine in Indonesia are still imported. The need for more awareness is propelling public and private organizations to adopt research programs to educate and enhance the therapeutics demand in the country.
The Lions Eye Institute has a long history of teaching surgical and other skills in Indonesia, and the new memorandums of understanding will reinforce ties and promote additional future innovations and training possibilities. Furthermore, key players operating in the market are focusing on developing novel therapeutics in the country.
Reasons to subscribe to Indonesia ophthalmic drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Indonesia ophthalmic drugs market databook
-
Our clientele includes a mix of ophthalmic drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Indonesia ophthalmic drugs market , including forecasts for subscribers. This country databook contains high-level insights into Indonesia ophthalmic drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Indonesia ophthalmic drugs market size, by drug class, 2018-2030 (US$M)
Indonesia Ophthalmic Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
